Tiotropium in asthma: what is the evidence and how does it fit in?

Tiotropium in asthma: what is the evidence and how does it fit in?

Despite current therapeutic approaches asthma remains uncontrolled in a significant proportion of patients. Short-acting anticholinergic bronchodilators have a very long history of use in asthma, and recent data confirms the importance of acetylcholine as both a bronchoconstrictor and as a regulator...

Full description

Bibliographic Details
Main Author: David M.G. Halpin
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S193945511930184X
id doaj-ea4fee43fc354b9fbf1afbe624138cc2
record_format Article
spelling doaj-ea4fee43fc354b9fbf1afbe624138cc22020-11-25T01:06:46ZengElsevierWorld Allergy Organization Journal1939-45512016-01-019Tiotropium in asthma: what is the evidence and how does it fit in?David M.G. Halpin0Professor Halpin is currently Consultant Physician & Honorary Associate Professor in Respiratory Medicine at the Royal Devon & Exeter Hospital. He leads a busy clinical department, continues research in respiratory medicine & has published widely. He lectures frequently around the world on COPD and asthma. Until recently he was an Associate Editor of Thorax. He was the Chairman and Clinical Expert for the COPD Guideline Development Group of the National Institute of Clinical Excellence (NICE) in the UK, and Respiratory Clinical Lead for the NHS in the South West Region of the UK.; Correspondence:Despite current therapeutic approaches asthma remains uncontrolled in a significant proportion of patients. Short-acting anticholinergic bronchodilators have a very long history of use in asthma, and recent data confirms the importance of acetylcholine as both a bronchoconstrictor and as a regulator of inflammation and remodeling in the lungs. Data from a comprehensive clinical trial programme, as well as use in primary care, show the efficacy and safety of tiotropium in adults with mild to moderate asthma when it is added to ICS and in severe asthma when it is added to high doses of ICS plus LABA, as well as in adolescents. Tiotropium is cost effective and its benefits are not restricted to particular phenotypes, making it a useful addition to the therapeutic options recommended by the Global Initiative for Asthma (GINA) for people with poorly controlled asthma at steps 4 & 5. Keywords: Asthma, Long-acting anticholinerics, Tiotropiumhttp://www.sciencedirect.com/science/article/pii/S193945511930184X
collection DOAJ
language English
format Article
sources DOAJ
author David M.G. Halpin
spellingShingle David M.G. Halpin
Tiotropium in asthma: what is the evidence and how does it fit in?
World Allergy Organization Journal
author_facet David M.G. Halpin
author_sort David M.G. Halpin
title Tiotropium in asthma: what is the evidence and how does it fit in?
title_short Tiotropium in asthma: what is the evidence and how does it fit in?
title_full Tiotropium in asthma: what is the evidence and how does it fit in?
title_fullStr Tiotropium in asthma: what is the evidence and how does it fit in?
title_full_unstemmed Tiotropium in asthma: what is the evidence and how does it fit in?
title_sort tiotropium in asthma: what is the evidence and how does it fit in?
publisher Elsevier
series World Allergy Organization Journal
issn 1939-4551
publishDate 2016-01-01
description Despite current therapeutic approaches asthma remains uncontrolled in a significant proportion of patients. Short-acting anticholinergic bronchodilators have a very long history of use in asthma, and recent data confirms the importance of acetylcholine as both a bronchoconstrictor and as a regulator of inflammation and remodeling in the lungs. Data from a comprehensive clinical trial programme, as well as use in primary care, show the efficacy and safety of tiotropium in adults with mild to moderate asthma when it is added to ICS and in severe asthma when it is added to high doses of ICS plus LABA, as well as in adolescents. Tiotropium is cost effective and its benefits are not restricted to particular phenotypes, making it a useful addition to the therapeutic options recommended by the Global Initiative for Asthma (GINA) for people with poorly controlled asthma at steps 4 & 5. Keywords: Asthma, Long-acting anticholinerics, Tiotropium
url http://www.sciencedirect.com/science/article/pii/S193945511930184X
work_keys_str_mv AT davidmghalpin tiotropiuminasthmawhatistheevidenceandhowdoesitfitin
_version_ 1725188316496658432

Similar Items